This is a Phase I, randomized, double-blind, placebo-controlled, study to estimate the
effects of daily oral dosing of 800 mg pazopanib on electrocardiographic parameters (QTc
interval duration) as compared with placebo in subjects with solid tumors. Moxifloxacin, will
serve as a positive control.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination